NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Quantumzyme's AI-Driven Enzyme Engineering Platform Expansion for Green API Manufacturing
TL;DR
Quantumzyme's expanded AI enzyme platform offers pharmaceutical companies a competitive edge through sustainable API manufacturing with improved cost efficiency and reduced environmental impact.
Quantumzyme's platform uses AI-driven computational modeling, in silico directed evolution, and high-throughput validation to design optimized biocatalysts that replace traditional chemical reaction steps.
This technology advances green pharmaceutical manufacturing by reducing hazardous waste, toxic solvent use, and carbon emissions, creating a cleaner environment for future generations.
Quantumzyme is expanding its AI enzyme platform beyond ibuprofen to target high-volume APIs like phenylephrine using computational biology for greener drug manufacturing.
Found this article helpful?
Share it with your network and spread the knowledge!
Quantumzyme is expanding its proprietary AI-powered enzyme design platform to target additional high-volume Active Pharmaceutical Ingredients (APIs) beyond ibuprofen, marking a major milestone in advancing green pharmaceutical manufacturing.
This expansion addresses the environmental impact of traditional API manufacturing by reducing hazardous waste, toxic solvent use, and carbon emissions at scale, while supporting domestic manufacturing and supply chain resilience goals.
The platform integrates advanced AI-driven computational modeling, in silico directed evolution, mechanistic simulation, and high-throughput validation to deliver optimized biocatalysts that replace traditional energy-intensive chemical reaction steps.
The expanded pipeline includes multiple high-volume APIs, including chiral intermediates such as phenylephrine and related compounds accessible via ketoreductases, which are widely used in the global generics sector.
The approach offers reduced chemical waste and solvent usage, lower carbon footprint, elimination of toxic reagents, and improved cost and yield efficiency compared to traditional manufacturing methods.
Naveen Kulkarni, CEO of Quantumzyme, stated their vision is to 'redefine chemical manufacturing through sustainable innovation' and advance greener chemistry while supporting supply chain resiliency.
The announcement was made on November 11, 2025, and Quantumzyme trades on the OTCQB market under the symbol QTZM.
The platform supports domestic API manufacturing and aligns with U.S. supply chain resilience and sustainability goals by providing a sustainable alternative to overseas manufacturing using legacy chemistries.
Quantumzyme Corp. is a pioneering biotransformation company that specializes in green chemistry, harnessing quantum mechanics, molecular modeling, AI-driven simulations, and computational enzyme engineering to design high-performance biocatalysts.
For more information and updates, visit www.quantumzymecorp.com and the Company's profile at www.otcmarkets.com/stock/QTZM.
Curated from NewMediaWire
